Heart MRI breakthrough: new scan could replace needle biopsy for rare heart disease

NCT ID NCT04862273

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a special type of heart MRI, called T1 mapping, can accurately diagnose cardiac amyloidosis—a condition where abnormal proteins build up in the heart muscle. Researchers studied 112 older adults with heart failure and thickened heart walls. They compared the MRI results to standard tests like a heart biopsy or a special scan. If T1 mapping proves reliable, it could offer a safer, non-invasive way to diagnose this serious condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Native T1 cardiac magnetic resonance imaging (CMR)

What this could lead to

If successful, this MRI technique could become a faster, non-invasive way to diagnose cardiac amyloidosis, reducing the need for biopsies.

What could go wrong

This is a completed study with 112 participants, so results are preliminary. The technique may not be as accurate as standard methods in all patients, and its usefulness depends on further validation.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

advanced heart failure Amyloid Neuropathies, Familial amyloidosis diastolic heart failure heart failure Hypertrophy, Left Ventricular mild heart failure moderate heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Leipzig

    Leipzig, Saxony, 04103, Germany